Autopsy report · NCT02885324

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

“Failure to meet accrual goals.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 3 years 3 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 2 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Indiana University

Sponsor type

University, hospital or other

Conditions

Glioblastoma Multiforme; Anaplastic Astrocytoma; Malignant Brain Tumor; High Grade Glioma

Interventions

Cabozantinib

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
  “Unable to meet accrual goals” (79% match in meaning)
• Afatinib in Advanced Refractory Urothelial Cancer
  “Unable to meet accrual goal after several years” (71% match in meaning)
• Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
  “Did not meet accrual goals.” (70% match in meaning)
• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (70% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.